Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

Bullish option flow detected in Amgen (AMGN) with 8,403 calls trading, 2x expected, and implied vol increasing over 3 points to 49.64%. Jan-25 ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

A native of De Pere, Wisconsin, Kinziger is considered a four-star recruit by 247Sports, On3 and ESPN. 247Sports ranks the ...

HOUSTON--Conexus MedStaff partners with Taimaka in support of providing critical malnutrition care to children in Gombe state ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

More than 40,000 Gen Z and millennial Bumble users worldwide, including over 2,000 singles in India, participated in the survey.